Please use this identifier to cite or link to this item:
Title: Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy
Authors: Chen, Vanessa HE
Lee, Grace KH
Tan, Choon-Han
Leow, Aloysius ST
Tan, Ying-Kiat 
Goh, Claire
Gopinathan, Anil 
Yang, Cunli
Chan, Bernard PL
Sharma, Vijay K 
Tan, Benjamin YQ
Yeo, Leonard LL 
Keywords: intra-arterial
ischemic stroke
thrombolytic therapy
Issue Date: 22-Feb-2021
Publisher: Ovid Technologies (Wolters Kluwer Health)
Citation: Chen, Vanessa HE, Lee, Grace KH, Tan, Choon-Han, Leow, Aloysius ST, Tan, Ying-Kiat, Goh, Claire, Gopinathan, Anil, Yang, Cunli, Chan, Bernard PL, Sharma, Vijay K, Tan, Benjamin YQ, Yeo, Leonard LL (2021-02-22). Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy. Stroke. ScholarBank@NUS Repository.
Abstract: Background and Purpose: In patients with acute ischemic stroke with large vessel occlusion, the role of intra-arterial adjunctive medications (IAMs), such as urokinase, tPA (tissue-type plasminogen activator), or glycoprotein IIb/IIIa inhibitors, during mechanical thrombectomy (MT) has not been clearly established. We aim to evaluate the efficacy and safety of concomitant or rescue IAM for acute ischemic stroke with large vessel occlusion patients undergoing MT. Methods: We searched Medline, Embase, and Cochrane Stroke Group Trials Register databases from inception until March 13, 2020. We analyzed all studies with patients diagnosed with acute ischemic stroke with large vessel occlusion in the anterior or posterior circulation that provided data for the two treatment arms, (1) MT+IAM and (2) MT only, and also reported on at least one of the following efficacy outcomes, recanalization and 90-day modified Rankin Scale, or safety outcomes, symptomatic intracranial hemorrhage and 90-day mortality. Data were collated in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: Sixteen nonrandomized observational studies with a total of 4581 patients were analyzed. MT only was performed in 3233 (70.6%) patients, while 1348 (29.4%) patients were treated with both MT and IAM. As compared with patients treated with MT alone, patients treated with combination therapy (MT+IAM) had a higher likelihood of achieving good functional outcome (risk ratio, 1.13 [95% CI, 1.03–1.24]) and a lower risk of 90-day mortality (risk ratio, 0.82 [95% CI, 0.72–0.94]). There was no significant difference in successful recanalization (risk ratio, 1.02 [95% CI, 0.99–1.06]) and symptomatic intracranial hemorrhage between the two groups (risk ratio, 1.13 [95% CI, 0.87–1.46]). Conclusions: In acute ischemic stroke with large vessel occlusion, the use of IAM together with MT may achieve better functional outcomes and lower mortality rates. Randomized controlled trials are warranted to establish the safety and efficacy of IAM as adjunctive treatment to MT.
Source Title: Stroke
ISSN: 00392499
DOI: 10.1161/strokeaha.120.031738
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A21) IA tpa during EVT metanalysis.pdf447.12 kBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.